Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Bicycle Therapeutics, with five buys, three holds and one sell among nine analysts. The average 12-month price target is $13.86, well above the stock’s reported $4.17 price.
• BCYC’s latest quarterly results fell short of expectations: the company reported a loss of $0.72 per share versus the expected $0.58 loss, while revenue of $0.63 million trailed the $4.22 million consensus estimate.
• The stock recently traded up 5%, but remains near its 52-week low, with a market capitalization of about $291 million. Institutional investors own 86.15% of the company, while insiders have recently sold shares primarily to cover tax obligations.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been given an average recommendation of "Hold" by the nine analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $13.8571.

A number of research firms recently weighed in on BCYC. Citigroup reaffirmed a "market outperform" rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Needham & Company LLC decreased their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Wall Street Zen raised Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th. Jefferies Financial Group reiterated a "buy" rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th.

Bicycle Therapeutics Trading Up 5.0%

BCYC opened at $4.17 on Friday. The company has a fifty day moving average price of $4.13 and a two-hundred day moving average price of $4.84. Bicycle Therapeutics has a 1-year low of $3.74 and a 1-year high of $9.16. The company has a market cap of $291.11 million, a P/E ratio of -1.53 and a beta of 1.55.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.14). The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. On average, research analysts forecast that Bicycle Therapeutics will post -2.23 EPS for the current fiscal year.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the firm's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer directly owned 605,408 shares of the company's stock, valued at approximately $2,585,092.16. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 9,977 shares of company stock valued at $42,702 over the last 90 days. 22.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in BCYC. Marquette Asset Management LLC acquired a new position in Bicycle Therapeutics during the 2nd quarter valued at about $309,000. FNY Investment Advisers LLC raised its stake in shares of Bicycle Therapeutics by 247.4% in the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company's stock worth $111,000 after purchasing an additional 18,693 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Bicycle Therapeutics by 512.9% in the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company's stock worth $33,000 after purchasing an additional 6,447 shares during the last quarter. Flax Pond Capital LLC lifted its holdings in shares of Bicycle Therapeutics by 1.4% in the first quarter. Flax Pond Capital LLC now owns 176,136 shares of the company's stock valued at $817,000 after purchasing an additional 2,503 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of Bicycle Therapeutics in the first quarter valued at approximately $331,000. Institutional investors own 86.15% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source